Esperion Therapeutics, Inc. (ESPR)

Market Cap	663.91M
Revenue (ttm)	303.80M
Net Income (ttm)	-105.83M
Shares Out	235.43M
EPS (ttm)	-0.54
PE Ratio	n/a
Forward PE	8.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,879,632
Open	2.880
Previous Close	2.900
Day's Range	2.720 - 2.930
52-Week Range	0.693 - 3.940
Beta	1.04
Analysts	Buy
Price Target	6.50 (+130.5%)
Earnings Date	Nov 6, 2025

About ESPR

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LD...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 26, 2013
• Employees: 304
• Stock Exchange: NASDAQ
• Ticker Symbol: ESPR
• Website: https://www.esperion.com

Financial Performance

In 2024, Esperion Therapeutics's revenue was $332.31 million, an increase of 185.66% compared to the previous year's $116.33 million. Losses were -$51.75 million, -75.27% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for ESPR stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 130.50% from the latest price.

Price Target

$6.5

(130.50% upside)

Analyst Consensus: Buy